drugset / Trial / NCT06319469

The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention

NCT06319469

Phase 2 Completed 140 enrolled Beni-Suef University
RandomizedParallel-groupOpen-labelTreatment

Summary

Acute urine retention, AUR, is often considered the most serious consequence of aging men with progressive benign prostatic hyperplasia (BPH). AUR is defined as the sudden and painful inability to void freely. This study aims to evaluate whether pyridostigmine bromide added to silodosin is beneficial in treating acute urine retention caused by BPH.

Timeline

Start
2023-02-01
Primary completion
2024-01-30
Completion
2024-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Pyridostigmine Small molecule 60 mg
Subject Silodosin Unknown 8 mg